Literature DB >> 21078415

Quantifying the cost in power of ignoring continuous covariate imbalances in clinical trial randomization.

Jody Ciolino1, Wenle Zhao, Renee' Martin, Yuko Palesch.   

Abstract

Motivated by potentially serious imbalances of continuous baseline covariates in clinical trials, we investigated the cost in statistical power of ignoring the balance of these covariates in treatment allocation design for a logistic regression model. Based on data from a clinical trial of acute ischemic stroke treatment, computer simulations were used to create scenarios varying from the best possible baseline covariate balance to the worst possible imbalance, with multiple balance levels between the two extremes. The likelihood of each scenario occurring under simple randomization was evaluated. The power of the main effect test for treatment was examined. Our simulation results show that the worst possible imbalance is highly unlikely, but it can still occur under simple random allocation. Also, power loss could be nontrivial if balancing distributions of important continuous covariates were ignored even if adjustment is made in the analysis for important covariates. This situation, although unlikely, is more serious for trials with a small sample size and for covariates with large influence on primary outcome. These results suggest that attempts should be made to balance known prognostic continuous covariates at the design phase of a clinical trial even when adjustment is planned for these covariates at the analysis.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21078415      PMCID: PMC4288592          DOI: 10.1016/j.cct.2010.11.005

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  23 in total

1.  Blood-pressure reduction and cardiovascular risk in HOPE study.

Authors:  P Sleight; S Yusuf; J Pogue; R Tsuyuki; R Diaz; J Probstfield
Journal:  Lancet       Date:  2001 Dec 22-29       Impact factor: 79.321

2.  Blood pressure and cardiovascular risk in the HOPE study.

Authors:  Roy Taylor
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

3.  Blood pressure and cardiovascular risk in the HOPE study.

Authors:  Ingrid Mühlhauser
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

4.  Minimization method for balancing continuous prognostic variables between treatment and control groups using Kullback-Leibler divergence.

Authors:  Akira Endo; Fumio Nagatani; Chikuma Hamada; Isao Yoshimura
Journal:  Contemp Clin Trials       Date:  2006-05-20       Impact factor: 2.226

5.  New algorithm for treatment allocation reduced selection bias and loss of power in small trials.

Authors:  J Hofmeijer; P C Anema; I van der Tweel
Journal:  J Clin Epidemiol       Date:  2007-08-23       Impact factor: 6.437

6.  Rank-Minimization for balanced assignment of subjects in clinical trials.

Authors:  Bjarne Stigsby; Donald R Taves
Journal:  Contemp Clin Trials       Date:  2010-01-06       Impact factor: 2.226

7.  Predictors of good outcome after intravenous tPA for acute ischemic stroke.

Authors:  A M Demchuk; D Tanne; M D Hill; S E Kasner; S Hanson; M Grond; S R Levine
Journal:  Neurology       Date:  2001-08-14       Impact factor: 9.910

8.  Methods and processes for the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.

Authors:  Vicki Hertzberg; Timothy Ingall; William O'Fallon; Kjell Asplund; Lewis Goldfrank; Thomas Louis; Teresa Christianson
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

9.  NINDS clinical trials in stroke: lessons learned and future directions.

Authors:  John R Marler
Journal:  Stroke       Date:  2007-10-25       Impact factor: 7.914

10.  Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage.

Authors:  Stephan A Mayer; Nikolai C Brun; Kamilla Begtrup; Joseph Broderick; Stephen Davis; Michael N Diringer; Brett E Skolnick; Thorsten Steiner
Journal:  N Engl J Med       Date:  2008-05-15       Impact factor: 91.245

View more
  9 in total

1.  Minimal sufficient balance-a new strategy to balance baseline covariates and preserve randomness of treatment allocation.

Authors:  Wenle Zhao; Michael D Hill; Yuko Palesch
Journal:  Stat Methods Med Res       Date:  2012-01-26       Impact factor: 3.021

2.  Continuous covariate imbalance and conditional power for clinical trial interim analyses.

Authors:  Jody D Ciolino; Renee' H Martin; Wenle Zhao; Edward C Jauch; Michael D Hill; Yuko Y Palesch
Journal:  Contemp Clin Trials       Date:  2014-03-07       Impact factor: 2.226

3.  Measuring continuous baseline covariate imbalances in clinical trial data.

Authors:  Jody D Ciolino; Reneé H Martin; Wenle Zhao; Michael D Hill; Edward C Jauch; Yuko Y Palesch
Journal:  Stat Methods Med Res       Date:  2011-08-24       Impact factor: 3.021

4.  Impact of minimal sufficient balance, minimization, and stratified permuted blocks on bias and power in the estimation of treatment effect in sequential clinical trials with a binary endpoint.

Authors:  Steven D Lauzon; Wenle Zhao; Paul J Nietert; Jody D Ciolino; Michael D Hill; Viswanathan Ramakrishnan
Journal:  Stat Methods Med Res       Date:  2021-11-29       Impact factor: 2.494

5.  Covariate imbalance and adjustment for logistic regression analysis of clinical trial data.

Authors:  Jody D Ciolino; Renée H Martin; Wenle Zhao; Edward C Jauch; Michael D Hill; Yuko Y Palesch
Journal:  J Biopharm Stat       Date:  2013       Impact factor: 1.051

6.  Assessment and implication of prognostic imbalance in randomized controlled trials with a binary outcome--a simulation study.

Authors:  Rong Chu; Stephen D Walter; Gordon Guyatt; P J Devereaux; Michael Walsh; Kristian Thorlund; Lehana Thabane
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

7.  Bias, precision and statistical power of analysis of covariance in the analysis of randomized trials with baseline imbalance: a simulation study.

Authors:  Bolaji E Egbewale; Martyn Lewis; Julius Sim
Journal:  BMC Med Res Methodol       Date:  2014-04-09       Impact factor: 4.615

8.  Bryostatin Placebo-Controlled Trials Indicate Cognitive Restoration Above Baseline for Advanced Alzheimer's Disease in the Absence of Memantine1.

Authors:  Richard E Thompson; Alan J Tuchman; Daniel L Alkon
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.472

9.  Multi-arm covariate-adaptive randomization.

Authors:  Feifang Hu; Xiaoqing Ye; Li-Xin Zhang
Journal:  Sci China Math       Date:  2022-07-21       Impact factor: 1.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.